Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hepatitis E virus (HEV) replication machinery is primarily composed of the non-structural polyprotein encoded by Open Reading Frame 1 (ORF1) (UniProt: P0C1Z1). This polyprotein is a multi-domain enzyme complex essential for viral genome replication and transcription, containing methyltransferase (MeT), papain-like cysteine protease (PCP), helicase (Hel), and RNA-dependent RNA polymerase (RdRp) domains (PubMed: 32824397). These domains coordinate the capping of viral RNA, the unwinding of double-stranded RNA intermediates, and the synthesis of new positive-sense RNA genomes (NCBI: NBK537279). As the central engine of the HEV life cycle, the ORF1 polyprotein is the primary target for therapeutic intervention, particularly in chronic cases affecting immunocompromised individuals (PubMed: 30103439). While current treatments like ribavirin and interferon-alpha are used, they are not specific to HEV and are associated with significant side effects and resistance mutations, such as the G1634R substitution in the RdRp domain (PubMed: 27535008). Consequently, the development of direct-acting antivirals (DAAs) targeting the specific enzymatic activities of the HEV replication machinery remains a critical area of clinical research.
Inhibition of RNA-dependent RNA polymerase (RdRp) activity, induction of lethal mutagenesis, and inhibition of viral RNA capping and helicase functions.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis E virus non-structural polyprotein (ORF1) (HEV ORF1).